Capricor Therapeutics (CAPR) Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock

Capricor Therapeutics, a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, announced today the publication, of a manuscript, which shows that cardiosphere-derived exosomes (CDC-EVs) can attenuate kidney damage and promote new blood vessel formation in a preclinical model of acute trauma, both of which are important factors in post-shock recovery. The publication titled, “Extracellular vesicles derived from cardiosphere-derived cells as a potential antishock therapeutic” was published in the international peer-reviewed journal, The Journal of Trauma and Acute Care Surgery in collaboration with researchers at the United States Army Institute of Surgical Research (USAISR).

“I am very excited to share the published results of this important study,” said Linda Marbán, Ph.D., Capricor’s CEO, “This has been a key collaboration between the USAISR and Capricor and shows the importance of CDC-EVs as a potential anti-shock therapeutic. The military continues to look for therapeutics that can be delivered in the field to stabilize wounded warriors. While cell therapy held promise in that arena, a lyophilized product that does not require ultra-cold storage is preferable. We believe that our CDC-EVs could potentially be that product. While further work is required to elucidate the full extent of possible clinical implications for CDC-EVs in treating trauma, these results certainly are a very important first step in that evaluation. We are delighted to work with the USAISR and look forward to extending this collaboration.”

Multiple other publications have shown that exosomes isolated from cardiosphere-derived cells have shown promising results in various pre-clinical studies using established animal models of diseases by exerting anti-inflammatory, anti-fibrotic, pro-angiogenic, and anti-apoptotic effects.

The goal of the study was to determine the therapeutic potential of CDC-EVs in a rat model of acute traumatic coagulopathy induced by polytrauma and hemorrhagic shock. CDC-EVs were not functionally procoagulant and did not interfere with platelet function, a pathological feature of acute polytrauma which was not ameliorated by another source of EVs, made from MSCs, in vitro. The findings suggest early delivery could improve outcomes of polytrauma and hemorrhagic shock, which is possible in the field due to the ease of utility, possibly being carried in a medic’s pack.

Dr Marbán continued, “We believe that the mechanism of action of our lead product CAP-1002 are these exosomes, and we have seen positive clinical data with these cells in multiple studies. Of note, we are currently enrolling our Phase II, INSPIRE study with CAP-1002 treating, severe COVID-19 patients. Since one of the pathological sequalae to trauma is a hyperimmune response similar to that which we see in COVID-19 patients, we look forward to sharing the data from INSPIRE when it becomes available.”

SourceGlobe Newswire

Chance TC, Wu X, Keesee JD, Garcia-Marcano J, Salgado CL, Liu B, Moseley JJ, Peck KA, R-Borlado L, Atai NA, Gould SJ, Marban LS, Cap AP, Rathbone CR, Bynum JA. (2021) Extracellular vesicles derived from cardiosphere-derived cells as a potential antishock therapeutic. J Trauma Acute Care Surg 91(2S Suppl 2):S81-S88. [abstract]

Leave a Reply

Your email address will not be published. Required fields are marked *